EUCTR2009-015589-74-DK进行中（未招募）不适用
A controlled, randomized, double-blind, cross-over study of the onset of analgesic effect of two formulations of ibuprofen for the treatment of pain after oral surgery.
ycomed Sweden Holding 2 AB0 个研究点目标入组 140 人开始时间: 2009年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Indication for surgical removal of two impacted or partly impacted mandibular
- •third molars
- •2) Written informed consent after verbal and written information.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A.Exclusion criteria related to Ibuprofen
- •1) An active gastric or duodenal ulcer
- •2) Hypersensivity to NSAIDs or ASA
- •3) Severe liver or kidney disorder
- •4) Bleeding disorder
- •5) Treatment with anticoagulantia
- •B. General exclusion criteria
- •1) Pregnancy, actual or intended
- •2) Systemic diseases which could endanger the participating patients
- •3) Patients who were assumed not to be able to carry out the study for instance
- •patients who were not speaking or writing local language
- •4) Patients who are regarded to have high risk for alveolitis (dry socket pain) e.g.
- •heavy smokers and diabetic patients
- •5) Intake of analgesics including NSAIDs for 12 hours before tooth removal of surgery
- •6) Lack of ability or willingness to comply with the protocol
- •7) Alcohol intake on the day of surgery.
- •8) Drug abusers
- •9) Other circumstances observed during the surgery, at the discretion of the
- •investigator.
研究者
相似试验
进行中（未招募）
不适用
A controlled, randomized, double-blind, cross-over study of the onset of analgesic effect of two formulations of ibuprofen for the treatment of pain after oral surgery.PainMedDRA version: 12.0Level: LLTClassification code 10033371Term: PainEUCTR2009-015589-74-SEycomed Sweden Holding 2 AB140
已完成
1 期
The effect of berryfruit extract on airways inflammation and airways obstruction in asthmaRespiratory - AsthmaAlternative and Complementary Medicine - Other alternative and complementary medicineAsthmaACTRN12613000451707The New Zealand Institute for Plant & Food Research Ltd28
进行中（未招募）
1 期
A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy.The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2013-004888-31-ITMundipharma Research GmbH & Co. KG217
进行中（未招募）
1 期
A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.EUCTR2013-004888-31-GBMundipharma Research GmbH & Co. KG220
进行中（未招募）
1 期
A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.The intended indication is:Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2013-004888-31-ESMundipharma Research GmbH & Co. KG200